Short answer
ADC Therapeutics SA (ADCT) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $21M (up 33.4% year over year) with net income of −$25M.
Q3 2026 key financials · XBRL
- Revenue
- $21M
- +33.4% YoY · +12.7% QoQ
- Net income
- −$25M
- +38.2% YoY · −52.8% QoQ
- Operating margin
- -68.3%
- EPS (diluted)
- −$0.16
- +42.9% YoY · −45.5% QoQ
Source: XBRL data from the ADC Therapeutics SA (ADCT) Q3 2026 10-Q on SEC EDGAR. USD.
ADC Therapeutics SA Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $21.7M, up 32.2% YoY from $16.4M, driven by ZYNLONTA product revenue of $21.0M, up 33.4%
- Operating margin 66.1% loss vs 188.6% loss YoY, with operating loss $14.4M vs $31.0M
- Best performer: ZYNLONTA product revenue $21.0M vs $15.8M, up 33.4%; license revenue $0.7M in both periods
- Nine-month operating cash use $69.4M vs $110.1M; cash and equivalents $189.2M at September 30
- October financing raised $76.3M; $70.0M term-loan prepayment reduced outstanding principal to $50.0M
- Outlook: fiscal 2026 R&D expense expected to decrease; headwinds include inflation, tariffs and ongoing royalty and debt obligations
Risk Factors
- Newly added LOTIS-5 regulatory risk: FDA cited increased Grade 5 adverse events and marginal benefit
- Most material update: Potential withdrawal of ZYNLONTA’s accelerated 3L+ DLBCL approval
- Compliance risk: Confirmatory trial required to verify clinical benefit and maintain current approval
- Operational risk: LOTIS-5 results may impair enrollment in other ZYNLONTA trials
- Commercial risk: Negative benefit-risk perception could reduce ZYNLONTA sales
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ADC Therapeutics SA quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.